About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker UTHR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hyper…
NCT07923591 · Pulmonary Hypertension Associated With Chronic Obstructive…
treprostinil SMI (treprostinil inhalation spray), Placebo (…
UTHR
United Therapeutics
Phase 2Not yet recruiting40May 2028Registry ↗
Nov 6, 2026An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary H…
NCT07923526 · Pulmonary Hypertension Associated With Chronic Obstructive…
treprostinil SMI (treprostinil inhalation spray)
UTHR
United Therapeutics
Phase 2/3Not yet recruiting400Sep 2034Registry ↗
Oct 19, 2026Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693 · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
UTHR
United Therapeutics
Phase 3Enrolling by invitation1,850Dec 2029Registry ↗
Oct 15, 2026Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulm…
NCT05255991 · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Placebo, Inhaled Treprostinil
UTHR
United Therapeutics
Phase 3Completed597Jun 30, 2025Registry ↗
Oct 6, 2026A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-…
NCT03683186 · PAH, Pulmonary Hypertension
Ralinepag
UTHR
United Therapeutics
Phase 3Enrolling by invitation1,000Dec 2026Registry ↗
Sep 9, 2026Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
NCT07224763 · ESRD (End-Stage Renal Disease), Kidney Transplantation
GGTA1 KO Thymokidney
UTHR
United Therapeutics
Phase 1/2Recruiting50Nov 2029Registry ↗
Aug 26, 2026DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Inter…
NCT06388421 · Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pu…
Prospective study assessments
UTHR
United Therapeutics
—Recruiting900Sep 1, 2030Registry ↗
Jul 13, 2026Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fib…
NCT05943535 · Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Placebo, Inhaled Treprostinil
UTHR
United Therapeutics
Phase 3Recruiting698Nov 2027Registry ↗
Jul 6, 2026Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 P…
NCT04084678 · Pulmonary Hypertension, Pulmonary Arterial Hypertension
Ralinepag, Placebo
UTHR
United Therapeutics
Phase 3Terminated10Apr 12, 2023Registry ↗
Jun 16, 2026A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patien…
NCT03626688 · PAH, Pulmonary Hypertension
Ralinepag, Placebo
UTHR
United Therapeutics
Phase 3Completed687Dec 31, 2025Registry ↗
May 28, 2026Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225 · Interstitial Lung Disease, Pulmonary Hypertension
Right heart catheterization (RHC)
UTHR
United Therapeutics
—Completed314Mar 13, 2026Registry ↗
May 27, 2026Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmona…
NCT03794583 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disea…
Inhaled treprostinil solution
UTHR
United Therapeutics
Phase 3Terminated41Nov 29, 2022Registry ↗
May 5, 2026Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782 · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Placebo, Inhaled Treprostinil
UTHR
United Therapeutics
Phase 3Completed598Feb 2, 2026Registry ↗
Apr 2, 2026ADAPT - A Patient Registry of the Real-world Use of Orenitram®
NCT03045029 · Pulmonary Arterial Hypertension
Oral treprostinil
UTHR
United Therapeutics
—Active, not recruiting300Mar 2027Registry ↗
Mar 27, 2026Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
NCT06878560 · ESRD (End-Stage Renal Disease), Kidney Transplantation
10 GE Xenokidney
UTHR
United Therapeutics
Phase 1/2Recruiting50Oct 2028Registry ↗
Dec 9, 2025A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil The…
NCT05203510 · Pulmonary Arterial Hypertension
Parenteral Treprostinil, Oral Treprostinil
UTHR
United Therapeutics
Phase 4Active, not recruiting52Apr 30, 2026Registry ↗
Mar 30, 2025Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to…
NCT02276872 · PAH
oral treprostinil
UTHR
United Therapeutics
Phase 2Completed32Jul 20, 2017Registry ↗
Jan 16, 2025Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
NCT05060315 · Pulmonary Arterial Hypertension
Remunity Pump for Remodulin
UTHR
United Therapeutics
—Terminated9Dec 31, 2024Registry ↗
Nov 1, 2024Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Cur…
NCT03950739 · Pulmonary Arterial Hypertension
Treprostinil Inhalation Powder
UTHR
United Therapeutics
Phase 1Completed51Aug 22, 2023Registry ↗
Jun 18, 2024Open-Label Study of Oral Treprostinil in Digital Ulcers
NCT00848107 · Systemic Sclerosis
treprostinil diethanolamine
UTHR
United Therapeutics
Phase 2Terminated115Sep 2011Registry ↗
Mar 5, 2024Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
NCT02261883 · Persistent Pulmonary Hypertension of the Newborn
IV Remodulin, Placebo
UTHR
United Therapeutics
Phase 2Terminated42Sep 27, 2022Registry ↗
Jan 5, 2024TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial…
NCT03055221 · Pulmonary Arterial Hypertension
Intravenous Treprostinil
UTHR
United Therapeutics
Phase 4Completed20Feb 25, 2014Registry ↗
Jan 3, 2024A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
NCT01934582 · Pulmonary Arterial Hypertension
UT-15C SR, treprostinil diethanolamine
UTHR
United Therapeutics
Phase 3Completed13Nov 2013Registry ↗
Jan 3, 2024Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
NCT00643604 · Hypertension, Pulmonary
treprostinil sodium
UTHR
United Therapeutics
Phase 4Terminated7Jan 2010Registry ↗
Jan 3, 2024Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Fiv…
NCT00439946 · Pulmonary Arterial Hypertension
treprostinil, Crono Five ambulatory pump
UTHR
United Therapeutics
Phase 4Terminated8Sep 2009Registry ↗
Jan 3, 2024FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension…
NCT00325403 · Pulmonary Hypertension
Oral treprostinil (UT-15C) Sustained Release Tablets, Place…
UTHR
United Therapeutics
Phase 3Completed349Apr 2011Registry ↗
Jan 2, 2024Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial…
NCT00147199 · Pulmonary Hypertension
Inhaled treprostinil, Placebo inhalation solution
UTHR
United Therapeutics
Phase 3Completed235Oct 2007Registry ↗
Dec 28, 2023Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
NCT00775463 · Systemic Sclerosis, Scleroderma
treprostinil diethanolamine, placebo
UTHR
United Therapeutics
Phase 2Completed148Mar 2011Registry ↗
Dec 27, 2023Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
NCT01477333 · Pulmonary Arterial Hypertension
UT-15C SR, Tyvaso Inhalation Solution
UTHR
United Therapeutics
Phase 2Completed18Nov 2013Registry ↗
Dec 19, 2023Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
NCT01884038 · Liver Transplant
treprostinil sodium, Placebo
UTHR
United Therapeutics
Phase 2/3Withdrawn0Jun 2010Registry ↗
Nov 24, 2023A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participant…
NCT03496623 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disea…
Inhaled treprostinil solution, Placebo solution
UTHR
United Therapeutics
Phase 3Terminated188Oct 13, 2022Registry ↗
Aug 7, 2023EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arte…
NCT03497689 · Pulmonary Arterial Hypertension
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
UTHR
United Therapeutics
Phase 4Completed36May 11, 2022Registry ↗
Dec 2, 2022An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02633293 · Pulmonary Hypertension, Interstitial Lung Disease
Inhaled Treprostinil
UTHR
United Therapeutics
Phase 2/3Terminated243Aug 1, 2021Registry ↗
Jul 27, 2022Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02630316 · Pulmonary Hypertension, Interstitial Lung Disease
Inhaled Treprostinil, Placebo
UTHR
United Therapeutics
Phase 2/3Completed326Dec 26, 2019Registry ↗
Jun 2, 2022An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
NCT01560637 · Pulmonary Arterial Hypertension
UT-15C (treprostinil diolamine)
UTHR
United Therapeutics
Phase 3Completed471Aug 12, 2021Registry ↗
Dec 22, 2021Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
NCT02279745 · Pulmonary Arterial Hypertension
Ralinepag
UTHR
United Therapeutics
Phase 2Completed45Mar 29, 2021Registry ↗
Oct 12, 2021A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High…
NCT03857841 · Bronchopulmonary Dysplasia
UNEX-42, Phosphate-buffered saline
UTHR
United Therapeutics
Phase 1Terminated3May 20, 2021Registry ↗
May 10, 2021An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial…
NCT01027949 · Pulmonary Arterial Hypertension
Oral Treprostinil
UTHR
United Therapeutics
Phase 3Completed894Feb 12, 2020Registry ↗
Mar 16, 2021Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
NCT03888365 · Pulmonary Arterial Hypertension
Treprostinil, Non-Treprostinil PAH Medications
UTHR
United Therapeutics
—Completed43Sep 19, 2019Registry ↗
Dec 9, 2020Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Ce…
NCT03098030 · Small Cell Lung Cancer
Dinutuximab, Irinotecan
UTHR
United Therapeutics
Phase 2/3Completed483Jan 27, 2020Registry ↗
Nov 10, 2020Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preser…
NCT03037580 · Pulmonary Hypertension, Heart Failure With Preserved Ejecti…
Oral treprostinil, Placebo
UTHR
United Therapeutics
Phase 3Terminated84Dec 3, 2019Registry ↗
Oct 22, 2020Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
NCT03043651 · Pulmonary Hypertension Associated With HFpEF
Oral treprostinil
UTHR
United Therapeutics
Phase 3Terminated48Mar 2, 2020Registry ↗
Jul 14, 2020Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
NCT02279160 · Pulmonary Arterial Hypertension
APD811, Placebo
UTHR
United Therapeutics
Phase 2Completed61Jun 2017Registry ↗
Feb 13, 2020Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monothe…
NCT01560624 · Pulmonary Arterial Hypertension
Treprostinil Diolamine, Placebo
UTHR
United Therapeutics
Phase 3Completed690Jun 24, 2018Registry ↗
Aug 5, 2019Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Pati…
NCT02693171 · Neuroblastoma
Dinutuximab
UTHR
United Therapeutics
—Terminated13Dec 19, 2016Registry ↗
Nov 1, 2017Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (…
NCT02999906 · Pulmonary Arterial Hypertension
Oral Treprostinil, Placebo
UTHR
United Therapeutics
Phase 3Withdrawn0Dec 2021Registry ↗
Oct 17, 2017Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects…
NCT02847260 · Pulmonary Arterial Hypertension
Remodulin
UTHR
United Therapeutics
Phase 4Completed39Mar 2014Registry ↗
Aug 2, 2017FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a P…
NCT00325442 · Pulmonary Hypertension
Oral treprostinil (UT-15C) sustained release tablets, Place…
UTHR
United Therapeutics
Phase 3Completed354Sep 2008Registry ↗
May 9, 2017Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin…
NCT02893995 · Pulmonary Arterial Hypertension
Slow Dose Titration Group of Subcutaneous Treprostinil, Rap…
UTHR
United Therapeutics
Phase 4Withdrawn0Apr 2018Registry ↗
May 9, 2017An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin®…
NCT02882126 · Pulmonary Arterial Hypertension
Subcutaneous Treprostinil
UTHR
United Therapeutics
Phase 4Withdrawn0Jun 2021Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:48 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances